Evaluating the Promise and Perils of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist: A Deep Dive into Therapeutic Potentials and Adverse Effects
Main Applicant – Dr Huang Jian, Senior Scientist I, Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR)

Glucagon-like peptide-1 (GLP-1) receptor agonists have received much attention for their beneficial effects on type 2 diabetes (T2D) and, more recently, on weight loss.

Studies have also suggested the therapeutic potentials of GLP-1 receptor agonists for cardiovascular diseases, neurodegenerative disorders, and cancers. However, evidence for the benefits of GLP-1 receptor agonists is still inconclusive and unexpected adverse events have also been reported. Therefore, we propose to comprehensively assess the therapeutic potentials and adverse effects of GLP-1 receptor agonists. Given that Asian populations are more susceptible to metabolic syndromes, evidence from large population-based cohorts such as SG100K is crucial for drug repurposing and safety in the local context.

In brief, we propose to tackle this research question by incorporating genetics, phenotypes, and electronic health records. This design will allow us to triangulate different sources of evidence. We propose to investigate multiple domains of health outcomes, including cardiometabolic health, cognitive function and neurological disorders, mental illness, bone health, body composition and physical performance, and cancer. Findings from this research will also provide insights for the global community.